PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
FDA assigns GDUFA goal date of April 29, 2024
Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs
Related news for (PHRRF)
- PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
- PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
- PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
- PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
- PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia